Prevision Medicine has raised USD 5.4M to commercialise its cancer-treatment testing platform. Instead of relying only on how similar patients responded, the test exposes living cells from a patient's tumour to a library of treatments and measures their response.
The Zurich company plans to use the funding for regulatory clearances, reimbursement coverage and expansion across Europe. Its PrevisionOne test is intended to help clinicians evaluate treatment options for blood cancers and solid tumours, using measurements from the individual patient's cells.
